Patient P-02674

Synthetic patientMETA-24 · Day 123 · 65–74 · F · baseline S02Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

64%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S02
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −24% vs expected — Dietary Support Protocol NP-02
Day 64 Tolerance state changed — Unstable → Improving
Day 71 SC-12 recommended — Supportive Compound SC-12
Day 72 Patient accepted — Started SC-12 in the companion
Day 78 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 84 Tolerance state changed — Unstable → Improving
Day 86 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 91 ME-01 recommended — Monitoring Escalation ME-01
Day 92 Patient accepted — Started ME-01 in the companion
Day 95 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 86.

Primary contributors, last 14 days

Treatment adherence-17
Inflammatory activity-12
GI instability-11
Nutritional resilience+9
Toxicity+2

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −24%
Supportive Compound SC-12Day 71
Result: symptom burden −17%
Monitoring Escalation ME-01Day 91
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

84%

probability of meaningful tolerance improvement

284 similar trajectories
87% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

56 min

improving · +2.4 vs previous 14 d

Sleep duration

Wearable

6.8 h

stable · +0.1 vs previous 14 d

Energy level

Daily log

4/10

worsening · -0.2 vs previous 14 d

Steps

Wearable

6,520

improving · +313 vs previous 14 d

GI burden

Companion

38.2/100

worsening · +7.9 vs previous 14 d

Adherence

Companion

56.2 %

worsening · -15.8 vs previous 14 d

Sleep quality

Wearable

41.6/100

worsening · -2.0 vs previous 14 d

Glucose, CGM daily mean

CGM

138 mg/dL

stable · +1.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 46 from the failing basin, 42 from restoration.

Would help

GI-04 GI Support Protocol
76% improved among 62 similar · onset 8 d · confidence 83%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 70%
DT-01 Dosing / Timing Recommendation
75% improved among 8 similar · onset 5 d · confidence 70%
More protein
GI -4.9 next day on high-intake days · n 29

Would not help

Keep fat low
GI +5.4 next day on high-intake days · n 21
Keep histamine low
GI +5.2 next day on high-intake days · n 16
Keep ultra-processed low
GI +3.7 next day on high-intake days · n 16

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+5.4detractor · 95%
Histamine load
+5.2detractor · 95%
Protein
-4.9supporter · 95%
Ultra-processed food
+3.7detractor · 95%
Insoluble fibre
-1.5no signal · 39%
Caffeine
-0.9no signal · 18%
Simple carbohydrates
-0.7no signal · 16%
Alcohol
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 43
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 37/100
Autonomic recovery ↓25
- WearableResting HR 82 bpm
Drug metabolism and exposure ↑20
- BloodToxicity index 45

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 37/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 50 ms
Sleep: 6.3 h
Steps: 5,605
Resting HR: 84 bpm

Daily log: GI score 38, nutritional resilience 50, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02483	27%	S06	BR-03	no change	64
P-02087	24%	S01	BR-03	no change	40
P-02054	37%	S01	CR-01	improved	57
P-02154	34%	S16	CR-01	improved	57
P-02233	34%	S16	CR-01	improved	66
P-02009	32%	S08	CR-01	improved	64
P-02151	31%	S04	CR-01	improved	49
P-02025	29%	S15	CR-01	improved	61
P-02339	26%	S03	DT-01	improved	50
P-02491	26%	S09	DT-01	no change	65
P-02274	25%	S15	DT-01	improved	50
P-02395	25%	S12	DT-01	improved	57